Sutimlimab Biosimilar - Research Grade

Human

C1s

>1mg/ml

Human IgG4

Riliprubart Biosimilar - Research Grade (ICH5273)

https://www.imgt.org/mAb-DB/

ICH3002

P09871

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of sutimlimab, supplied strictly for research use only and not intended for human or veterinary use. Sutimlimab is a humanized monoclonal antibody that binds complement component C1s and blocks the classical complement pathway; this research-grade analog is built around the same C1s target as the originator drug and carries a human IgG4 framework. It is offered as a bulk, low-endotoxin reagent (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg) suitable for functional and preclinical experimentation. Typical applications include use as a positive or benchmarking control in classical-pathway complement assays, target-binding and neutralization studies against C1s, screening and comparability work, and as a tool for interrogating classical-pathway biology in vitro and in preclinical models. Availability in milligram-to-gram quantities supports assay development, structure-function studies, and repeat-experiment consistency. As an IgG4-framework analog it is not a therapeutic and should not be used to infer clinical performance. C1s (complement C1s subcomponent, UniProt P09871) is a serine protease of the classical complement pathway. Within the C1 complex, six C1q recognition subunits associate with a tetramer of two C1r and two C1s molecules (C1r2s2). When C1q engages antigen-bound IgG or IgM immune complexes, autoactivation of C1r cleaves and activates C1s. Activated C1s then cleaves complement C4 into C4a and C4b, and C2 into C2a and C2b, generating the C4b2a C3 convertase that drives downstream amplification, opsonization, anaphylatoxin release, and formation of the membrane attack complex. Because C1s sits at the proximal enzymatic step of the classical pathway, it is a focal point for controlling antibody-mediated complement activation, and its inhibition selectively dampens classical-pathway activity while leaving the lectin and alternative pathways largely intact.

EDSPD2, complement C1s

Detects human C1s. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Sutimlimab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Sutimlimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Sutimlimab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Sutimlimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Sutimlimab that binds human C1s.